Lisata Therapeutics, Inc. (LSTA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+89.2%

$1.91

vs $1.01 price

Levered DCF

$1.85

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-74.76

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.97×	-1.24×	-1.06×	-0.24×	-1.69×	-2.71×	-1.29×	-2.13×
P/B	1.09×	0.84×	0.46×	0.2×	0.5×	0.68×	1.24×	0.91×
P/S	95.05×	24.82×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-0.01×	-0.42×	0.02×	0.33×	-0.78×	-0.32×	-0.64×	-1.44×
Gross margin	14.1%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	-10711.2%	-2240.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	-9756.5%	-1998.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	5.76×	6.16×	8.18×	11.26×	21.27×	10.08×	4.35×	7.85×
Debt / equity	0×	0×	0×	0.01×	0.01×	0.02×	0.05×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	-3,397.4×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-111.7%	-67.6%	-43.3%	-81.4%	-29.8%	-25.1%	-96.6%	-42.9%
Return on invested capital	-117.3%	-73.0%	-47.9%	-82.4%	-29.7%	-24.9%	-93.3%	-43.6%
Return on assets	-93.5%	-57.1%	-38.1%	-74.2%	-28.3%	-22.6%	-74.0%	-36.3%
Free cash flow yield	-98.9%	-78.0%	-90.9%	-163.7%	-48.0%	-40.1%	-72.9%	-58.3%
Earnings yield	-102.6%	-80.5%	-94.6%	-413.8%	-59.1%	-36.9%	-77.6%	-46.9%
Enterprise value	$201.8K	$8.7M	-$385.7K	-$18.6M	$22.5M	$6.2M	$12.9M	$24.2M
Net debt / EBITDA	0.92×	0.78×	0.98×	0.56×	0.83×	0.83×	0.65×	0.61×
Cash conversion cycle (days)	-1,045	329	0	0	0	-5,910	-8,367	-1,236